Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (151-160 of 325) with videos related to

Pageof 33
Sort By:
Experimental Hematology|May 7, 2022
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemiaCamilia M Soof, Tanya M Spektor, Sameer A Parikh, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
British Journal of Haematology|February 6, 2016
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experienceDaniel L Van Dyke, Lillian Werner, Laura Z Rassenti, et al.
Cancer Genetics and Cytogenetics|June 2, 2006
Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemiaStephanie R Fink, Stephanie A Smoley, Kimberly J Stockero, et al.
Haematologica|April 24, 2024
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemiaGordon J Ruan, Xiaosheng Wu, Kimberly A Gwin, et al.
British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
British Journal of Haematology|April 4, 2008
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaShanique Palmer, Curtis A Hanson, Clive S Zent, et al.
British Journal of Haematology|October 4, 2007
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaKami Maddocks-Christianson, Susan L Slager, Clive S Zent, et al.
Pageof 33

Showing results (151-160 of 325) with videos related to

Sort By:
Pageof 33
Experimental Hematology|May 7, 2022
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemiaCamilia M Soof, Tanya M Spektor, Sameer A Parikh, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
British Journal of Haematology|February 6, 2016
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experienceDaniel L Van Dyke, Lillian Werner, Laura Z Rassenti, et al.
Cancer Genetics and Cytogenetics|June 2, 2006
Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemiaStephanie R Fink, Stephanie A Smoley, Kimberly J Stockero, et al.
Haematologica|April 24, 2024
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemiaGordon J Ruan, Xiaosheng Wu, Kimberly A Gwin, et al.
British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
British Journal of Haematology|April 4, 2008
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaShanique Palmer, Curtis A Hanson, Clive S Zent, et al.
British Journal of Haematology|October 4, 2007
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaKami Maddocks-Christianson, Susan L Slager, Clive S Zent, et al.
Pageof 33